Key result
Empagliflozin had a neutral impact on left ventricular global longitudinal strain and exercise capacity compared to sitagliptin in patients with type 2 diabetes and normal heart function.
Why the study?
The mechanisms by which SGLT2 inhibitors prevent heart failure and influence cardiac structure and function remain unclear.
Does empagliflozin improve myocardial contractility and cardiopulmonary fitness in subjects with type 2 diabetes without heart disease?
RCT (n=44)
Open-label
Randomized
No
Does empagliflozin improve myocardial contractility and cardiopulmonary fitness in subjects with type 2 diabetes without heart disease?
Answers are grounded in this paper and cite their sources.
Empagliflozin has a neutral impact on LV-GLS and exercise tolerance in T2D patients with normal LV function, though it may improve contractility in those with subclinical dysfunction.
Background The mechanism through which sodium-glucose cotransporter 2 inhibitors (SGLT2i) prevent the incidence of heart failure and/or affect cardiac structure and function remains unclear. Methods The EMPA-HEART trial is aimed at verifying whether empagliflozin improves myocardial contractility (left ventricle global longitudinal strain, LV-GLS) and/or cardiopulmonary fitness (peak oxygen uptake, VO2peak) in subjects with type 2 diabetes (T2D) without heart disease. Patients with T2D, normal LV systolic function (2D-Echo EF > 50%), and no heart disease were randomized to either empagliflozin 10 mg or sitagliptin 100 mg for 6 months and underwent repeated cardiopulmonary exercise tests with echocardiography and determination of plasma biomarkers. Results Forty-four patients completed the study, 22 per arm. Despite comparable glycaemic control, modest reductions in body weight (− 1.6; [− 2.7/− 0.5] kg, p = 0.03) and plasma uric acid (− 1.5; [− 2.3/− 0.6], p = 0.002), as well as an increase in haemoglobin (+ 0.7; [+ 0.2/+ 1.1] g/dL, p = 0.0003) were evident with empagliflozin. No difference was detectable in either LV-GLS at 1 month (empagliflozin vs sitagliptin: + 0.44; [− 0.10/+ 0.98]%, p = 0.11) and 6 months of therapy (+ 0.53; [− 0.56/+ 1.62]%), or in VO 2peak (+ 0.43; [− 1.4/+ 2.3] mL/min/kg, p = 0.65). With empagliflozin, the subgroup with baseline LV-GLS below the median experienced a greater increase (time*drug p < 0.05) in LV-GLS at 1 month (+ 1.22; [+ 0.31/+ 2.13]%) and 6 months (+ 2.05; [+ 1.14/+ 2.96]%), while sitagliptin induced a modest improvement in LV-GLS only at 6 months (+ 0.92; [+ 0.21/+ 0.62]%). Conclusions Empagliflozin has neutral impact on both LV-GLS and exercise tolerance in subjects with T2D and normal left ventricular function. However, in patients with subclinical dysfunction (LV-GLS < 16.5%) it produces a rapid and sustained amelioration of LV contractility. Trial registration EUDRACT Code 2016-002225-10
No takes yet. Share an insight, caveat, or question.
Nesti et al. (2022) conducted an RCT in Type 2 diabetes without heart disease (n=44). Empagliflozin vs. Sitagliptin 100 mg was evaluated on Left ventricle global longitudinal strain (LV-GLS) at 6 months (MD 0.53%, 95% CI -0.56 to 1.62). Empagliflozin had a neutral impact on left ventricular global longitudinal strain and exercise capacity compared to sitagliptin in patients with type 2 diabetes and normal heart function.
Synapse has enriched 10 related papers. Consider them for comparative context: